GOVX logo

GEOVAX LABS INC

GOVXNASDAQ
🏆 #5258 by market capUS Equity
$0.35▼ $0.02 (−5.31%)
Live
🔔
Track GOVX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.3%
7d▼ 4.3%
14d▼ 16.7%
30d▼ 51.7%
ytd▼ 92.1%
1y▼ 97.8%
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
-31.8%
Thin
💵FCF Margin
6.6%
Moderate
⚖️P/S Ratio
0.6x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$0.34 – $0.35
52-Week Range
$0.35 – $16.80
Volume
$3.05B
Avg Volume
$2.15B
Shares Outstanding
7.4M
Next Earnings
Nov 4, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$686,206
P/E Ratio
—
P/S Ratio
0.6x
EPS (TTM)
$-13.92
Dividend Yield
—
Dilution (1yr)
+127.4%

Why Investors Own GOVX

  • ✓High-growth profile — revenue up +58.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 63% gross margin and 5% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GOVX logo

GEOVAX LABS INC

GOVX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▼ −37.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-628.0%▼ −743.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$22M▼ −13.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$22M▼ −12.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
958K▲ +127.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$3M YoY
StockOtter · stockotter.space

About GEOVAX LABS INC

GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$0.44
▲ +26.2% Upside
High Target$0.48
Low Target$0.40
Based on 18 analysts

Latest News & Updates

🚀
Reuters·2h ago

GEOVAX LABS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift GOVX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

GEOVAX LABS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.